Anti-inflammatory peptides: mechanism, evidence, and what the human data is missing

Inflammation is the body’s response to damage and infection. The acute version is necessary — without it, wounds do not close and pathogens are not cleared. The chronic version is what most of the consumer-facing “anti-inflammatory” market is actually pointing at: the smouldering, low-grade inflammatory state that tracks with age, metabolic disease, joint dysfunction, and worse cardiovascular and cognitive outcomes.

Three peptides currently under FDA review have animal-model evidence touching that biology: KPV, BPC-157, and GHK-Cu. Each engages the inflammatory cascade at a different point. None has a controlled human trial in an inflammatory indication. Here is the mechanism story for each, and where the three prescribing files actually diverge.

What an anti-inflammatory mechanism actually has to do

Most chronic inflammation runs through a small set of common signalling pathways. NF-κB is the master switch — a transcription factor that, when activated by stress signals (damage, infection, oxidative load), pushes genes that make pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) and recruit immune cells (neutrophils, macrophages, lymphocytes) to the site. The cytokines amplify the signal. The recruited cells produce more cytokines. If the original signal resolves, the loop closes. If it does not, the loop keeps running.

An anti-inflammatory intervention has to do one of three things: dampen the upstream stress signal, suppress the NF-κB activation step, or interrupt the downstream cytokine-and-recruitment cascade. Most peptides claimed as anti-inflammatory act at the second step — they inhibit NF-κB activation, suppress cytokine production downstream, or modulate the immune cells that propagate the signal.

That is the biology three peptides under FDA review have animal-model evidence in. Each engages slightly differently.

KPV: the α-MSH-derived NF-κB inhibitor

KPV is three amino acids — Lys-Pro-Val — the C-terminal tripeptide of α-MSH (alpha-melanocyte-stimulating hormone). α-MSH itself is a 13-residue pituitary hormone with well-characterised anti-inflammatory effects in animal and cell-culture systems. KPV retains much of that anti-inflammatory activity while lacking the melanocortin-receptor pigmentary effects of the full hormone.

Brzoska and colleagues’ 2010 Adv Exp Med Biol review is the mechanism overview. In macrophage and immune-cell systems, KPV inhibits NF-κB signalling, suppresses pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6, IL-8), and dampens neutrophil chemotaxis. The mechanism story is consistent across multiple cell-culture systems and animal models.

The most-cited animal evidence is Kannengiesser and colleagues’ 2008 paper in Inflammatory Bowel Diseases. The melanocortin-derived tripeptide KPV showed dose-dependent reductions in inflammation scores and tissue damage in mouse colitis models — the most-cited animal-model evidence in the IBD-adjacent consumer market for the peptide.

What that work does not show: KPV efficacy in human inflammatory bowel disease, or in any other human inflammatory indication. No registered controlled human trial of KPV in any inflammatory indication exists.

BPC-157: anti-inflammatory as downstream of cytoprotection

BPC-157’s anti-inflammatory story is structured differently. The proposed mechanism, developed across three decades of animal work by Predrag Sikirić’s group at the University of Zagreb, runs through angiogenesis and the nitric oxide (NO) pathway. In Sikirić’s framing, the anti-inflammatory effects observed in rat injury models (tendon, ligament, intestinal, eye, brain tissue) are a downstream consequence of the NO-mediated cytoprotection programme rather than direct immune-cell modulation. The cells are damaged less, the inflammatory signal generated locally is smaller, the cascade does not amplify.

The 2025 Pharmaceuticals literature and patent review by Józwiak and colleagues surveys that animal evidence — multi-tissue anti-inflammatory observations across the rat literature. The 2025 Sikirić comment exchange in the same journal sets out the cytoprotection-and-NO interpretation explicitly. The exchange between the two groups frames the cancer-relevance question for BPC-157’s primary angiogenic mechanism, but it also articulates the anti-inflammatory framing the originating research group endorses.

The human anti-inflammatory file for BPC-157 is essentially empty. NCT07437547 — the Phase 2 trial of BPC-157 for acute hamstring muscle strain repair, recruiting from February 2026 — is the first registered controlled human trial of the molecule in an injury indication. Its endpoints are clinical recovery, not direct measurement of inflammatory markers in human tissue. Even a clean positive result would leave the anti-inflammatory claim itself inferred rather than measured. We covered the cancer-safety question that BPC-157’s angiogenic mechanism opens up in Angiogenesis and peptide therapy.

GHK-Cu: anti-inflammatory as part of a broader regenerative programme

GHK-Cu’s anti-inflammatory evidence lives at the cell-culture level and inside a much broader claim. Pickart, Vasquez-Soltero and Margolina (2015, BioMed Research International) document that GHK-Cu modulates metalloproteinases (the enzymes that remodel the extracellular matrix and that fire heavily during inflammatory tissue damage), attracts immune cells in wound-healing contexts, and contributes to the resolution phase of the inflammatory response in animal wound models.

Pickart and Margolina’s 2018 Int J Mol Sci review extends that into gene-expression data. GHK-Cu correlates with the activation of gene programmes that include the suppression of ageing-associated NF-κB signalling — the load-bearing chronic-inflammation framing in the longevity literature. The inflammaging hypothesis — that chronic, low-grade NF-κB-driven inflammation is a load-bearing mechanism of biological ageing — is the broader frame the GHK-Cu anti-inflammatory case sits inside.

What that work does not establish: GHK-Cu efficacy in human inflammatory indications. The single published randomised human trial of GHK-Cu (Miller 2006, n=13 after CO2 laser resurfacing) was null on every objective endpoint — including markers of post-procedural inflammation. We covered the full GHK-Cu file in Copper peptides: why GHK-Cu is not just a skincare trend.

Same biology, three different prescribing files

The anti-inflammatory mechanism story is real for each of the three peptides — and engages the inflammatory cascade at a different point for each. KPV inhibits NF-κB and cytokine production directly in macrophage and immune-cell systems. BPC-157 acts upstream by limiting the cellular damage that produces the inflammatory signal in the first place, through NO-mediated cytoprotection. GHK-Cu modulates the matrix-remodelling enzymes and gene-expression programmes that propagate or resolve the inflammatory response across tissue. Three mechanisms, three different cellular intervention points. None has a controlled human trial in an inflammatory indication.

The prescribing files diverge from there in the way the regulatory state breaks them.

KPV’s file is two animal mechanism papers — Brzoska 2010 review and Kannengiesser 2008 mouse IBD model — and a July 23, 2026 FDA PCAC docket slot for the indications wound healing and inflammatory conditions (the full string per the FR notice). The peptide is on the active review path, the reviewed indication is the closest of the three to the consumer marketing case, and the human evidence base is the thinnest of the three — essentially the Kannengiesser mouse model.

BPC-157’s file is three decades of rat anti-inflammatory + injury-recovery work from one dominant research group, an unresolved cancer-relevance debate between Józwiak’s group and Sikirić’s, a recruiting hamstring trial that will read clinical endpoints rather than inflammation markers directly, and a July 23, 2026 PCAC docket slot for ulcerative colitis — a mucosal-protection indication adjacent to but not the same as the joint and tendon inflammation the off-label market is buying for. We covered the PCAC review process in What is the PCAC.

GHK-Cu’s file is the deepest cell-culture inflammation-pathway evidence of the three (Pickart 2015, 2018 reviews including the NF-κB suppression gene-expression framing), a single null randomised human trial of topical skincare from 2006, an academic 2025 review concluding the published data on skin permeability and effectiveness is insufficient, and a Wave 2 PCAC review scheduled before the end of February 2027. The injectable route came off the Section 503A Category 2 ban list. The non-injectable route came off the Section 503A Category 1 enforcement-discretion list. Opposite-direction regulatory motion; both forms on the Feb 2027 docket.

Three peptides. Three different paths into the same inflammation biology. Three different conversations with a supervising physician about which file actually supports a prescription. Wolverine Health is being built so those conversations happen — physician-supervised peptide protocols, US-licensed compounding pharmacies, every batch third-party tested. Join the waitlist for a note the day any of those three inflammation files actually moves.